Search Results

You are looking at 1 - 10 of 33 items for :

  • "Epoetin alfa" x
Clear All
Full access

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre and James Rosberg

breast cancer chemotherapy: results of a feasibility intervention study . Oncol Nurs Forum 2003 ; 30 : 513 – 522 . 9 Demetri GD Kris M Wade J . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of

Full access

Daniel Shasha, Pierre Cremieux and Louis Harrison

. Impact of tumor hypoxia and anemia on radiation therapy outcomes . Oncologist 2002 ; 7 : 492 – 508 . 26 Demetri G Kris M Wade J , for the Procrit Study Group . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is

Full access

Rodger J. Winn

References 1 Littlewood TJ Bajetta E Nortier JW . Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo

Full access

.6004/jnccn.2005.0047 Cancer Patient Survival and Erythropoietin Glaspy John A. MD 11 2005 3 3 6 6 796 796 804 804 10.6004/jnccn.2005.0048 Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of

Full access

Carmen P. Escalante, Ellen Manzullo and Rosalie Valdres

toward guidelines for the management of fatigue . Oncology 1998 ; 12 : 369 – 377 . 4 Demetri GD Kris M Wade J Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type

Full access

Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson and George M. Rodgers

. 4. Henry DH Dahl NV Auerbach M . Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy . Oncologist 2007 ; 12 : 231 – 242 . 5

Full access

John A. Glaspy

. Crawford J Cella D Cleeland CS . Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy . Cancer 2002 ; 95 : 888 – 895 . 4. Cella D Zagari MJ Vandoros

Full access

Cancer and Anemia Treated With Epoetin Alfa Shasha Daniel * MD Cremieux Pierre † PhD Harrison Louis * MD 9 2004 2 2 5 5 509 509 517 517 10.6004/jnccn.2004.0040

Full access

John A. Glaspy

The author has received research support from Amgen, Ortho Biotech, and Hoffman La Roche. References 1 Cella D Zagari MJ Vandoros C . Epoetin alfa treatment results in clinically significant improvements in quality of life in

Full access

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller and Lenora A. Pluchino

-bmez were recently included in the NCCN Guidelines as appropriate substitutions for originator filgrastim and pegfilgrastim, respectively, for prevention of FN. In addition, epoetin alfa-epbx has also been included as an appropriate substitute for epoetin